Amgen Inc.

Teijin Pharma Limited

Howard Bregman

Nagasree Chakka

Erin F DiMauro

Matthew M Weiss

Hanh Nho Nguyen

Hakan Gunaydin

John Laird Buchanan

Zihao Hua

Angel Guzman-Perez

Daniel La

Isaac E Marx

Alessandro Boezio

Thomas Dineen

Xiao Mei Zheng

Bingfan Du

Xin Huang

Emily Anne Peterson

Hongbing Huang

Christiane Boezio

Katrina Woodin Copeland

Hua Gao

James R Coats

Matthew W Martin

Vinod Francis Patel

Patricia Lopez

Shon Booker

Ryan D White

Victor J Cee

Timothy David Cushing

Xiaolin Hao

Ryan Paul Wurz

Laurie B Schenkel

Brian M Fox

Russell Graceffa

Youngsook Shin

Hilary Plake Beck

Lewis D Pennington

Steven H Olson

Charles Kreiman

Stephanie Geuns-Meyer

Jason Brooks Human

Philip R Olivieri

Oleg Epstein

Ryota Nakajima

Holly L Deak

Kosuke Sasaki

Keiko Shimada

Kazuhisa Okada

Shuyan Yi

Hiroyuki Oono

Kenta Hibiya

Shinji Kakuda

Jun Hirata

Shon Keith Booker

Jason Human

The present invention provides compounds of Formula (Ia), and pharmaceutically acceptable salts thereof. The compounds are useful as inhibitors of voltage-gated sodium channels, in particular Nav 1.7. as described in the specification. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention, as well as intermediates and processes useful for making the compounds.

Biaryl acyl-sulfonamide compounds as sodium channel inhibitors

Compounds of Formula I are useful inhibitors of tankyrase. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein. 

Quinazolinone compounds and derivatives thereof

The present invention relates to a novel compound having a function of inhibiting ROR&#x3b3; activity. The present invention also relates to pharmaceutical composition comprising the compound, a use of the compound in treating or preventing autoimmune diseases, inflammatory diseases, metabolic diseases, or cancer diseases.

Pyrazole amide derivative

The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention. 

Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors

Compounds of Formula (I) and Formula (II) are useful inhibitors of tankyrase. Compounds of Formula (I) and Formula (II) have the following structure: where the definitions of the variables are provided herein. 

Oxazolidinone compounds and derivatives thereof

The present invention provides compounds that are inhibitors of voltage-gated sodium channels (Nav), in particular Nav 1.7, and are therefore useful for the treatment of diseases treatable by inhibition of these channels, in particular, chronic pain disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Carboxamides as inhibitors of voltage-gated sodium channels

The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7.  The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention.

Bicyclic aryl and heteroaryl sodium channel inhibitors

Growing community of inventors

Melrose, MA, United States of America

Howard Bregman